London-listed LiDCO Group (LID) has seen a surge in demand for its heart monitoring technology in China as a direct response to the COVID-19 virus outbreak.
The medical supplier said that its distribution partner in China, Beijing Gloryway Medical Company, has sold a small number of monitors in Wuhan, China, where the novel coronavirus originated, as a direct result of the outbreak.
LiDCO told investors that the additional purchase will provide intensive care monitoring capabilities in order to treat the most acute cases of the infection.
Prior to the outbreak of number COVID-19, a number of LiDCO rapid monitors had already been installed in Wuhan.
Shares in LiDCO Group were trading 9.52% higher at 5.75p during Monday trading.
LiDCO believes its supply chain and inventory levels would support a certain amount of above forecast demand should it arise in areas affected by Covid-19.
The company added that it is currently in discussions with healthcare institutions in a number of the affected areas.
Matt Sassone, Chief Executive Officer of LiDCO, said that whilst the proportion of intensive care patients for COVID-19 remains low, there is “significant clinical evidence that the use of advanced hemodynamic monitoring for patients in intensive care is clinically beneficial.”
He added, “Whilst the Board doesn't anticipate changing expectations at this time, the Company is prepared to support customers should they face an increased demand for intensive care."
According to CNN, as of Sunday, the total number of worldwide cases of COVID-19 stands at more than 105,000, with 3,599 deaths.
Follow News & Updates from LiDCO Group here: